Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNO-206 versus doxorubicin in advanced soft tissue sarcoma
2011-004927-11Phase 2Completed
- Sponsor
- LadRx
- Start
- Jan 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in soft tissue sarcoma (STS) comparing INNO-206 with Doxorubicin (2 arms). Primary endpoints: Tumor response, Progression-free survival and 3 more. Started Jan 2012; status: completed.
02
Drugs
aldoxorubicindoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2011-004927-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004927-11.